Zheng Quan Zhi Xing·2025-08-08 09:20Core Viewpoint - The company intends to utilize part of its idle raised funds for cash management to enhance fund efficiency and ensure shareholder interests are protected [3][6][8] Fundraising Overview - The company was approved to publicly issue 45,340,000 shares at a price of 9.37 RMB per share, raising a total of 424.84 million RMB, which has been fully deposited into a dedicated account [2][3] - The net proceeds will be allocated to specific projects, including a comprehensive production building and facilities, a complex formulation workshop, and R&D for high-end generic drugs, with a total investment of 738.25 million RMB [3] Cash Management Plan - The company plans to use up to 80 million RMB of idle funds for cash management within 12 months from the board's approval [4][6] - The investment will focus on low-risk, high-liquidity products with a maturity of no more than 12 months, such as structured deposits and time deposits [5][6] Implementation and Oversight - The board has authorized the chairman to make investment decisions within the approved limits, with the finance department responsible for execution [5][7] - The company will adhere to relevant regulations for information disclosure and will not alter the intended use of the raised funds [5][8] Impact on Operations - The cash management strategy will not affect the implementation of fundraising projects or the company's main business operations, aiming to improve overall performance and shareholder returns [6][8] Review and Approval Process - The board and its audit committee have approved the cash management plan, confirming it aligns with regulatory requirements and does not harm shareholder interests [7][8] - The sponsor institution has verified that the necessary approval procedures were followed and supports the cash management initiative [8]